Patient-prosthesis mismatch in new generation trans-catheter heart valves: a propensity score analysis

Alexis Theron^{1*†}, Johan Pinto^{1†}, Dominique Grisoli¹, Karolina Griffiths², Erwan Salaun³, Nicolas Jaussaud¹, Eléonore Ravis¹, Marc Lambert³, Lyna Messous¹, Cecile Amanatiou¹, Thomas Cuisset³, Vlad Gariboldi¹, Roch Giorgi^{2,4,5,6}, Gilbert Habib³, and Frederic Collart¹

¹Department of Cardiac Surgery, La Timone Hospital, La Timone Hospital 264, rue saint Pierre 13005 Marseille, France; ²APHM, Hôpital de la Timone, Service Biostatistique et Technologies de l'Information et de la Communication, Marseille, France; ³Department of Cardiology, La Timone Hospital, Marseille, France; ⁴Aix-Marseille Université, UMR_S 912 (SESSTIM), IRD, 13385 Marseille, France; ⁵INSERM, UMR_S 912 (SESSTIM), 13385 Marseille, France; and ⁶Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France

Received 15 September 2016; editorial decision 20 January 2017; accepted 24 January 2017; online publish-ahead-of-print 27 February 2017

Aims

When compared with the former Sapien XT (XT-THV), the Sapien 3 trans-catheter heart valve (S3-THV) embeds an outer annular sealing cuff to prevent para-valvular regurgitation (PVR). The consequences of this new feature on valve haemodynamics have never been evaluated. We aimed to compare both types of prostheses regarding patient-prosthesis mismatch (PPM).

Methods and results

Patients who underwent a TAVR for aortic stenosis were retrospectively included. Regression adjustment for the propensity score was used to compare 50 XT-THV patients with 71 S3-THV. At the 1-month follow-up, the mean indexed effective orifice area (iEOA) was $1.12 \pm 0.34 \text{ cm}^2/\text{m}^2$ with XT-THV and $0.96 \pm 0.27 \text{ cm}^2/\text{m}^2$ with S3-THV. The mean gradient was $11 \pm 5 \text{ mmHg}$ and $13 \pm 5 \text{ mmHg}$, respectively. Nine patients had moderate PPM, and two exhibited severe PPM with XT-THV. Nineteen patients had moderate PPM, and seven demonstrated severe PPM with S3-THV. There was a five-fold increased risk of PPM with S3-THV (OR = 4.98; [1.38–20.94], $P = 0.019$). S3-THV decreased the iEOA by $0.21 \text{ cm}^2/\text{m}^2$ [−0.21; (−0.38 to −0.05); $P = 0.012$] and increased the mean gradient by 4.95 mmHg [4.95; (2.27–7.64); $P < 0.001$]. The risk of PPM was increased 15.24-fold with 23 mm S3-THV [15.24; (2.92–101.52); $P = 0.002$] in comparison with the 23 mm XT-THV. PVR were reduced by 98% with S3-THV.

Conclusion

There is an increased risk of PPM with 23mm S3-THV in comparison with 23 mm XT-THV. This may be attributable to the additional sub-annular cuff that avoids the risk of PVR. Regarding the increased vulnerability of younger patients to PPM, we provide essential information on the extension of TAVR indication to the younger population.

Introduction

Trans-catheter aortic valve replacement (TAVR) has become a reliable treatment alternative to surgery for aortic stenosis in patients who are inoperable or at a high surgical risk.¹ Recently, the randomized PARTNER II trial showed similar all-cause death and disabling stroke outcomes of both techniques in intermediate-risk patients,

thus widening the TAVR indication to lower-risk patients.² However, the extension of the indications requires a reduction of several prevalent complications, such as para-valvular regurgitation (PVR), which is associated with a poorer prognosis.³

Recently, the new expandable Sapien 3 trans-catheter heart valve (S3-THV) has replaced the previous generation of Sapien XT trans-catheter heart valve (XT-THV), which was associated with a high

* Corresponding author. Tel: +33 4 91 38 57 17; Fax: +33491384926. E-mail: alexis.theron@ap-hm.fr

† These authors contributed equally to this work.

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.

Table 1 Baseline characteristics

	All n = 121	XT-THV n = 50	S3-THV n = 71	p
Age, years	82.4 ± 6.5	83.3 ± 6.6	81.7 ± 6.4	0.13
Females (%)	73 (60%)	39 (78%)	34 (48%)	<0.001
BSA, m ²	1.70 ± 0.22	1.63 ± 0.17	1.75 ± 0.24	0.04
Mellitus Diabetes	39 (32%)	19 (38%)	20 (28%)	0.25
Hypertension	85 (70%)	39 (78%)	46 (65%)	0.11
Smoke	10 (8%)	3 (6%)	7 (10%)	0.52
Dyslipidaemia	46 (38%)	24 (48%)	22 (31%)	0.05
Coronary artery disease	56 (46%)	26 (52%)	30 (42%)	0.29
Renal insufficiency	23 (19%)	13 (26%)	10 (14%)	0.09
Chronic pulmonary disease	14 (12%)	4 (8%)	10 (14%)	0.3
Cerebrovascular disease	5 (4%)	1 (2%)	4 (6%)	0.4
Porcelain aorta	3 (2%)	1 (2%)	2 (3%)	1
Atrial fibrillation	31 (26%)	10 (20%)	21 (30%)	0.23
NYHA				0.61
I	10 (8%)	4 (8%)	6 (8%)	
II	41 (34%)	15 (30%)	26 (37%)	
III	58 (48%)	24 (48%)	34 (48%)	
IV	12 (10%)	7 (14%)	5 (7%)	
Recent CHF	49 (40.5%)	29 (58%)	20 (28%)	0.001
Haemoglobin (g/L)	119 ± 17	116 ± 17	121 ± 17	0.04
BNP (pg/mL)	417 ± 364	454 ± 358	390 ± 369	0.11
Creatinine (μmol/L)	129 ± 126	131 ± 170	128 ± 82	0.26

BSA, body surface area; CHF, congestive heart failure.

0.001), which is consistent with a lower BSA ($1.63 \pm 0.17 \text{ m}^2$ vs. $1.75 \pm 0.24 \text{ m}^2$, $P = 0.04$), lower haemoglobin rate (116 ± 17 and $121 \pm 17 \text{ g/dL}$, $P = 0.04$), and lower aortic annulus diameter on TTE ($20.2 \pm 1.7 \text{ mm}$ vs. 21.5 ± 1.95 , $P < 0.001$) (Tables 1 and 2).

Procedural characteristics

Among the XT-THV patients, three patients had a 20 mm (6%), 24 had a 23 mm (48%), 21 had a 26 mm (42%), and two had a 29 mm (4%). Among the S3-THV patients, 34 had a 23 mm (48%), 30 had a 26 mm (42%), and six had a 29 mm (10%). Aortic annuli were larger with 23mm and 26mm S3-THV, shown by larger MSCT aortic annulus area ($P < 0.001$) and lower prosthesis to annulus oversizing. Figure 1A and B. There were no differences between the groups regarding procedural events, such as vascular complications or pacemaker implantation.

Clinical follow-up

At 1-month follow-up, five deaths (4%) had occurred, all in the XT-THV subgroup. Seventy-three patients (63%) clinically improved ($P < 0.001$), with a mean improvement of $21 \pm 4.7\%$. No difference was observed between the two prostheses in terms of functional improvement in the NYHA class (25 vs. 15%, $P = 0.6$). Propensity score analysis demonstrated that the S3-THV did not affect functional improvement when compared with the XT-THV [Coefficient = 0.09, (-0.17–0.35), $P = 0.49$].

Haemodynamic follow-up

The overall echocardiographic data and data according to valve type at 1-month follow-up are provided in Table 3. The mean gradient decreased significantly from baseline to 1-month follow-up (51.0 ± 16.0 vs. $12.0 \pm 5.0 \text{ mmHg}$, $P < 0.001$), and LVEF slightly increased (60 ± 12 vs. $56 \pm 13\%$, $P < 0.001$). At 1-month follow-up, the mean EOA was $1.71 \pm 0.52 \text{ cm}^2/\text{m}^2$, which corresponded to a mean iEOA of $1.2 \pm 0.31 \text{ cm}^2/\text{m}^2$. Thirty-seven patients (30.5%) had PPM, of which 28 (76%) had moderate and nine (15%) had severe PPM.

Among the 28 patients with moderate PPM, nine patients (32.1%) received a XT-THV (one with 20 mm, four with 23 mm, and four with 26 mm XT-THV), and 19 patients (67.9%) had S3-THV (12 with 23 mm, 5 with 26 mm, and 2 with 29 mm S3-THV). Among the nine patients with severe PPM, two (22.2%) had a XT-THV (20 mm XT-THV in all), and seven (77.8%) had a S3-THV (six with 23 mm and one with 26 mm S3-THV) Table 4 (see Supplementary data online, Appendix S3A and S3B).

No difference in BSA was observed between patients with and without PPM ($BSA = 1.73 \pm 0.18$ vs. $1.67 \pm 0.19 \text{ m}^2$, $P = 0.12$). The mean trans-prosthetic gradient was significantly higher in patients with PPM vs. no PPM (15.2 ± 5.3 vs. $11.2 \pm 4.5 \text{ mmHg}$, $P < 0.001$) (see Supplementary data online, Appendix S2).

S3-THV was significantly associated with lower iEOA (0.96 ± 0.27 and $1.12 \pm 0.34 \text{ cm}^2/\text{m}^2$, $P < 0.01$) and higher mean trans-aortic gradient (13 ± 5 vs. $11 \pm 5 \text{ mmHg}$, $P = 0.002$) than the XT-THV group in univariate analysis.

Using a linear regression adjustment of the propensity score, S3-THV decreased the iEOA by around $-0.21 \text{ cm}^2/\text{m}^2$ [Coefficient = -0.21 , (-0.38 to -0.05), $P = 0.013$] and increased the mean trans-prosthetic gradient by $+4.95 \text{ mmHg}$ [Coefficient = 4.95 , (2.27–7.64), $P < 0.001$] compared with XT-THV. Figure 2 Sensitivity analysis using a linear regression with IPTW of the propensity score had similar results for both decreasing the iEOA [-0.11 (-0.21 to -0.02), $P = 0.019$] and increasing the mean trans-prosthetic gradient [4.38 , (2.88–5.88), $P < 0.001$]. Consistent with these findings, S3-THV implantation was significantly associated with a higher risk of PPM [OR = 4.98, (1.38–20.94), $P = 0.019$] using logistic regression adjustment of the propensity score. Figure 3A Sensitivity analysis also identified a higher risk of PPM with S3-THV implantation in comparison with XT-THV [OR = 7.24, (3.62–15.38), $P \leq 0.00001$].

The same modalities of regression were used in the subgroup analysis with regard to prosthesis size. Among patients with a size of 23 mm, S3-THV decreased the iEOA by around $0.26 \text{ cm}^2/\text{m}^2$ [coefficient = -0.26 , (-0.44 to -0.08), $P = 0.005$] and increased the mean trans-prosthetic gradient by around 5.63 mmHg [coefficient = 5.63 , (2.8–8.45), $P < 0.001$] compared with the 23 mm XT-THV. There was a 15-fold increased risk of PPM with 23 mm S3-THV vs. 23 mm XT-THV [OR = 15.24, (2.92–101.52), $P = 0.002$]. Figure 3B Sensitivity analysis supports these results and also identified a lower iEOA [-0.16 , (-0.28 to -0.04), $P = 0.008$], a higher mean trans-prosthetic gradient [5.91 , (4.11–7.71), $P < 0.00001$] and a 25-fold increased risk of PPM [25.95 (9.43–86.90), $P < 0.00001$] in the 23 mm S3-THV compared with the 23mm XT-THV.

Among patients with 26 mm-THV, no significant difference was found concerning the EOAi [coefficient = -0.13 , (-0.31 to 0.06), $P = 0.18$] or PPM risk [OR = 1.77, (0.312–11.27), $P = 0.068$]. Figure 3C

Table 2 Echocardiography data at baseline

	All n = 121	XT-THV n = 50	S3-THV n = 71	P
LVEF (%)	56 ± 13	55 ± 13	56 ± 13	0.61
LVEF < 50% (%)	31 (25%)	12 (24%)	19 (26.7%)	0.4
LV septum diameter (mm)	14.8 ± 2.4	14.5 ± 2.4	15 ± 2.4	0.46
LV diastolic diameter (mm)	46.8 ± 6.7	48.3 ± 7.2	45.5 ± 6	0.16
LV systolic diameter (mm)	32 ± 6.9	33.6 ± 7	31 ± 6.7	0.32
LV mass (g/m ²)	178 ± 52	190 ± 51	168 ± 51	0.08
Aortic annulus diameter (mm)	20.9 ± 1.95	20.2 ± 1.7	21.5 ± 1.95	<0.001
EOA (cm ²)	0.69 ± 0.22	0.65 ± 0.19	0.71 ± 0.23	0.057
iEOA (cm ² /m ²)	0.41 ± 0.13	0.4 ± 0.12	0.42 ± 0.14	0.44
Mean trans-aortic gradient (mmHg)	51 ± 16	52 ± 16	51 ± 16	0.66
Aortic regurgitation	63 (52%)	35 (70%)	28 (39%)	<0.001
Aortic regurgitation grade				0.001
Trivial	40 (63%)	23(66%)	17 (61%)	
Mild	13 (21%)	5(14%)	8 (29%)	
Moderate	4 (6%)	4(11%)	0	
Severe	6 (4.9%)	3(9%)	3 (10%)	
Mitral regurgitation	57 (47%)	33(66%)	24 (34%)	<0.001
Mitral regurgitation 3–4	4 (3.3%)	1(2%)	3 (4.2%)	0.46
Systolic pressure of pulmonary artery	42 ± 14	44 ± 14	39 ± 15	0.08

LVEF, left ventricular ejection fraction; LV, left ventricle; EOA, effective orifice area; iEOA, indexed effective orifice area.

However, the 26 mm S3-THV increased the mean trans-prosthetic gradient by 4.54 mmHg [coefficient = 4.54, (1.64–7.44), *P* = 0.002] compared with the 26 mm XT-THV.

Sixty-one patients (53%) had a PVR at the 1-month follow-up, including 37 patients (82%) in the XT-THV group and 24 patients (34%) in the S3-THV. Among these patients, 47 (77%) had trivial PVR, twelve (20%) had mild/moderate PVR and 2 (3%) had severe PVR. Among the XT-THV group, 26 patients (70%) had trivial PVR, 9 (24%) had mild/moderate PVR and 2 (6%) had severe PVR. Neither moderate nor severe PVR were observed in the S3-THV group, whereas 21 (88%) had trivial PVR and 3 (12%) had mild PVR.

Using a logistic regression adjustment of the propensity score, the odds of a para-prosthetic leak were 98% reduced with S3-THV compared with XT-THV [OR = 0.02, (0.002–0.095), *P* < 0.001]. Figure 4 Sensitivity analysis results for PVR were consistent [OR = 0.03 (0.01–0.06), *P* < 0.00001] with much narrower confidence intervals.

Discussion

The aim of this study was to compare the occurrence of moderate and severe PPM with the new balloon-expandable S3-THV vs. the preceding XT-THV generation in TAVI for severe AS. The main findings were (i) a higher risk of PPM for S3-THV, (ii) a 15-fold increased risk of PPM with the smallest size of S3-THV prosthesis in comparison with the same size XT-THV prosthesis, and (iii) a similar degree of left ventricular mass regression and NYHA functional improvement with both valves.

The clinical effect of PPM after surgical aortic valve replacement (SAVR) has been a matter of controversy since the first description

by Rahimtoola in 1978.⁵ PPM occurs if the EOA of the implanted bio-prosthesis is small relative to the patient body size.

PPM is considered severe when the iEOA is < 0.65 cm²/m² and moderate if the iEOA is between 0.65 and 0.85 cm²/m². The occurrence of PPM post-SAVR is well recognized and ranges from 20 to 70% for moderate PPM and from 2 to 10% for severe PPM.¹² The adverse effects of PPM include functional impairment, reduced LV mass regression and a significant reduction of early and intermediate survival, particularly in severe PPM.¹³ A recent meta-analysis of 34 studies with 27 186 patients confirmed a significantly negative effect of PPM on long-term survival, particularly in cases of vulnerability, such as impaired LVEF, severe LV hypertrophy, concomitant mitral regurgitation, and/or paradoxical low flow/low gradient aortic stenosis.¹⁴

When compared with SAVR, the previous prostheses used for TAVR, such as Edwards Sapien and Sapien-XT, tend to have better haemodynamic performance, thus contributing to a reduction in PPM.¹⁵ In a randomized comparison of 699 patients from the PARTNER trial A cohort, TAVR was significantly associated with less PPM (46.4 vs. 60.0%, *P* < 0.001) and severe PPM (19.7 vs. 28.1%, *P* < 0.001) compared with SAVR.⁷ This study was also the first to identify an important relationship between PPM after TAVR implantation and 2-year mortality, but this relationship was found only in the TAVR nonrandomized continued access arm. The difference in severe PPM was particularly important in patients with small aortic annuli (<20 mm), assuming that the thinner stent frame and absence of a sewing ring in the annular space provide less blood flow obstruction. However, this study was based on the former generation of SAPIEN/ SAPIEN XT-THV, and none of these haemodynamic results could be extended to the new S3-THV generation, which embedded supplementary annular space material.

Figure 1 MSCT aortic annulus area for XT-THV and S3-THV according prosthesis size (A). Prosthesis to annulus oversizing (%) for both prosthesis size. Data are presented as mean ± SD.

Several studies have compared the two types of XT-THV and S3-THV by focusing on PVR occurrence but, to the best of our knowledge, our study is the first to compare the occurrence of PPM in both prosthesis groups.^{4,16} Our main finding was that S3-THV was associated with a higher risk of moderate and severe PPM than XT-THV implantation. We showed that the iEOA was significantly lower (1.12 ± 0.34 vs. 0.96 ± 0.27 cm²/m², $P = 0.009$) and the mean trans-prosthetic gradient was significantly higher (11.0 ± 5.5 and 13.5 ± 4.7 mmHg, $P = 0.002$) in S3-THV. Strikingly, S3-THV significantly decreased the iEOA by -0.21 cm²/m² and increased the mean trans-prosthetic gradient by $+4.95$ mmHg compared with the XT-THV. Consequently, the risk of PPM increased nearly 5-fold for S3-THV implantation. More specifically, the smallest aortic annulus patients who received a 23 mm S3-THV prosthesis demonstrated a 15-fold increased risk of PPM compared with 23 mm XT-THV whereas aortic annuli were significantly lower with XT-THV (324 ± 38.8 vs. 376.8 ± 38 mm², $P < 0.001$). Binder et al. previously showed a trend to a lower EOA and higher trans-prosthetic gradient in S3-THV compared with the XT-THV group (1.43 ± 0.4 vs. 1.51 ± 0.43 cm², $P = 0.38$ and 11.65 ± 5.98 vs. 9.96 ± 4.77 , $P = 0.08$ for 23 mm prosthesis), but the absence of EOA indexation to BSA did not permit the reporting of the incidence of PPM in this cohort.⁴

The increase in both the risk and severity of high trans-prosthetic gradients and PPM could be explained by the outer sealing cuff, which

is embedded in the new S3-THV. This new feature bulges into the annular space after deployment to fill up irregularities. In concordance with previous studies, the reduction in rate and severity of PVR was confirmed in our study (34 and 82%, $P < 0.001$).¹⁷ However, although this novelty achieved a lower rate of PVR, the presence of a supplementary material occupying the annular space could have favoured a systolic blood obstruction and detrimental haemodynamic performance, particularly in the case of a small aortic annulus.

A reduction in aortic annulus oversizing for the S3-THV compared with XT-THV could also explain the increase observed in post-operative gradients. Oversizing was often used with XT-THV to prevent PVR and valve embolization. However, the S3-THV requires less oversizing than the XT-THV because it has a skirt to prevent PVR. In our study, native aortic annuli were smallest for patients implanted with XT-THV than S3-THV. We reported a 38% reduction in annular aortic area oversizing for the S3-THV compared with XT-THV, similar to the results of Nijhoff et al.¹⁶ We could assumed that if similar sizing algorithm has been applied for S3 vs. XT, this would negatively impact the haemodynamics of the S3-THV relative to the XT-THV. In fact, the SAPIEN 3 is a device that shortens substantially when it is deployed. Oversizing may result in under-deployed and 'under-shortened' valve stent, which may in turn lead to suboptimal haemodynamic. Then, we compared mean iEOA in patients with 23 mm S3-THV without and with oversizing to show what would have happened if the former algorithm has been applied. Surprisingly, indexed EOA and mean trans-prosthetic gradients were similar in both group (0.85 ± 0.32 cm²/m² vs. 0.89 ± 0.21 cm²/m², $P = 0.59$ and 13.8 ± 5.3 mmHg vs. 16.55 ± 4.9 mmHg, $P = 0.15$) but some caution should be taken with regard to the limited size of our study. Similarly, Nijhoff et al. reported that oversizing was not associated with higher trans-prosthetic gradients or reduced EOA in their study.¹⁸ Finally, the rate of balloon post-dilatation was similar in both subgroups and does not explain the haemodynamic difference.

The relative LV mass reduction was comparable and incomplete with XT-THV and S3-THV, thus suggesting a persistence of LV after-load in both subgroups. One explanatory hypothesis is that S3-THV had the highest risk of PPM, whereas XT-THV experienced the highest occurrence of PVR.³ Both haemodynamic sequelae contribute to limiting LV hypertrophy regression, and further investigations are mandatory to evaluate the respective strength of each parameter on myocardial recovery and prognosis.¹⁹ Additionally, baseline aortic regurgitation was significantly more prevalent in the XT-THV group and could have prolonged the duration and limit the completeness of LV mass regression.²⁰ Finally, the follow-up period was short, and the implanted patients were older and mainly had hypertension. This attribute may have compromised optimal LV remodelling.

Taken together, our results suggest that S3-THV reduces the risk of PVR at the expense of having a higher risk of PPM. These findings have to be considered in an era of the extension of the indications to younger patients with less comorbidity, who are more vulnerable to PPM than the elderly.

Strengths and limitations

The main limitations are the retrospective, single-centre, non-randomized design of the study. However, the use of propensity score analysis is a well-established approach in observational research to address differences between treatments and to reduce bias

Concerning THV, many pre- or peri-procedural factors varying from one patient to another, such as the degree of stent deployment, the presence and/or the localization of native valve calcification, the height of valve implantation and the ring anatomy could influence directly the estimation of post-operative iEOA.¹¹ Consequently, no *in vivo* iEOA per size are provided by manufacturer for THV. For all these reasons, we didn't use the 'projected' iEOA to diagnose PPM after THV implantation even if the presently reported values for EOA might present a unique frame of reference with regards to the haemodynamic performance to be expected from these prostheses.

Several errors can occur in this estimation of iEOA, particularly for TAVR prosthesis where LVOT diameter and LVOT VTI assessment were particularly challenging. In this study, all echocardiography was performed in a core laboratory by two experienced cardiologists to limit the risk of intra/inter-observer variability. Another cause of the discrepancies in the iEOA measurement may be the occurrence of a low-flow state [i.e. stroke volume index (SVI) < 35 mL/m²]. In our

study, only nine patients demonstrated a post-implantation low-flow state (mean LVEF = $43.6 \pm 8.5\%$, mean LVOT diameter = 21.5 ± 2.5 mm, mean SVI = 28.1 ± 4.25 mL/m², mean iEOA = 0.82 cm²/m²). These patients belonged exclusively to the S3-THV group, which could suggest some technical difficulties in SVI calculation in this subgroup. However, the LVOT measurements method was the same for both type of prosthesis and LVOT VTI measurement was also standardized by positioning the pulsed-wave Doppler sample volume at 1.0 cm below the THV insertion.¹³ The main reasons to explain the absence of low-flow state with XT-THV were the higher occurrence of PVR and the lower BSA due to a female predominance. Similarly, the higher occurrence of PVR in the XT-THV group could have increased the mean trans-prosthetic gradient.

Finally, iEOA may also be underestimated if the ascending aorta diameter is < 30 mm because of the risk of pressure recovery phenomenon.²² Unfortunately, too many data were missing to provide reliable data concerning the estimation of the energy loss index.

Figure 3 Incidence of moderate and severe PPM with both prosthesis in overall population (A) and according to prosthesis size: 23 mm (B), 26 mm (C).

Figure 4 Incidence and severity of PVR according to prosthesis type.

Conclusion

In this single-centre, retrospective propensity score analysis, we observed an increased risk of PPM only in the smaller size (=23 mm) S3-THV compared with the former generation of XT-THV but not in

the larger sizes where the incidence of PPM remains low. In return, the additional sub-annular cuff of the S3-THV prosthesis significantly reduced the occurrence and severity of PVR. Given the enhanced vulnerability of younger patients to the consequences of PPM, these observations should be useful when considering the extension of the TAVR indication to a younger population.

Supplementary data

Supplementary data are available at *European Heart Journal - Cardiovascular Imaging* online.

Conflict of interest: None declared.

References

1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;**363**:1597–607.
2. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med* 2016;**374**:1609–20.
3. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. *N Engl J Med*. 2012;**366**:1686–95.
4. Binder RK, Stortecky S, Heg D, Tueller D, Jeger R, Toggweiler S et al. Procedural results and clinical outcomes of transcatheter aortic valve implantation in Switzerland: an observational cohort study of sapien 3 versus sapien XT transcatheter heart valves. *Circ Cardiovasc Interv* 2015;**8**:e002653.
5. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. *Circulation* 1978;**58**:20–24.

6. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. *Heart* 2006;**92**:1022–9.
7. Pibarot P, Weissman NJ, Stewart WJ, Hahn RT, Lindman BR, McAndrew T et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort—a analysis. *J Am Coll Cardiol* 2014;**64**:1323–34.
8. Amat-Santos IJ, Dahou A, Webb J, Dvir D, Dumesnil JG, Allende R et al. Comparison of hemodynamic performance of the balloon-expandable SAPIEN 3 versus SAPIEN XT transcatheter valve. *Am J Cardiol* 2014;**114**:1075–82.
9. Binder RK, Webb JG, Willson AB, Urena M, Hansson NC, Norgaard BL et al. The impact of integration of a multidetector computed tomography annulus area sizing algorithm on outcomes of transcatheter aortic valve replacement: a prospective, multicenter, controlled trial. *J Am Coll Cardiol* [Internet]. 2013;**62**:431–8.
10. Pieter Kappetein A, Head SJ, Généreux P, Piazza N, Van Mieghem NM, Blackstone EH et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. *EuroIntervention* 2012;**8**:782–795.
11. Clavel M-A, Rodés-Cabau J, Dumont É, Bagur R, Bergeron S, De Larochellière R et al. Validation and characterization of transcatheter aortic valve effective orifice area measured by Doppler echocardiography. *JACC Cardiovasc Imaging* 2014;**4**:1053–62.
12. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. *Circulation* 2003;**108**:963–8.
13. Mohty D, Dumesnil JG, Echahidi N, Mathieu P, Dagenais F, Voisine P, Pibarot P. Impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: influence of age, obesity, and left ventricular dysfunction. *J Am Coll Cardiol* 2009;**53**:39–47.
14. Head SJ, Mokhles MM, Osnabrugge RLJ, Pibarot P, Mack MJ, Takkenberg JJM et al. The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. *Eur Heart J* 2012;**33**:1518–29.
15. Clavel M-A, Webb JG, Pibarot P, Altwegg L, Dumont E, Thompson C et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprotheses for the treatment of severe aortic stenosis. *J Am Coll Cardiol* [Internet]. 2009;**53**:1883–91.
16. Nijhoff F, Abawi M, Agostoni P, Ramjankhan FZ, Doevendans PA, Stella PR. Transcatheter aortic valve implantation with the new balloon-expandable Sapien 3 versus Sapien XT valve system: a propensity score-matched single-center comparison. *Circ Cardiovasc Interv* 2015;**8**:e002408.
17. Binder RK, Rodés-Cabau J, Wood DA, Mok M, Leipsic J, De Larochellière R et al. Transcatheter aortic valve replacement with the SAPIEN 3: A new balloon-expandable transcatheter heart valve. *JACC Cardiovasc Interv* 2013;**6**:293–300.
18. Rodés-Cabau J, Pibarot P, Suri RM, Kodali S, Thourani VH, Szeto VY et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER Trial. *Circ Cardiovasc Interv* 2014;**7**:701–11.
19. Poulin F, Yingchoncharoen T, Wilson WM, Horlick EM, Généreux P, Tuzcu EM et al. Impact of prosthesis-patient mismatch on left ventricular myocardial mechanics after transcatheter aortic valve replacement. *J Am Heart Assoc* 2016;**5**:e002866.
20. Une D, Mesana L, Chan V, Maklin M, Chan R, Masters RG et al. Clinical impact of changes in left ventricular function after aortic valve replacement: analysis from 3112 patients. *Circulation* 2015;**132**:741–7.
21. Weintraub WS, Grau-Sepulveda M V, Weiss JM, O'Brien SM, Peterson ED, Kolm P et al. Appendix—Comparative effectiveness of revascularization strategies. *N Engl J Med* 2012;**366**:1467–76.
22. Baumgartner H, Stefenelli T, Niederberger J, Schima H, Maurer G. 'Overestimation' of catheter gradients by Doppler ultrasound in patients with aortic stenosis: a predictable manifestation of pressure recovery. *J Am Coll Cardiol* 1999;**33**:1661.